A
ALX Oncology Holdings Inc. (ALXO)
NMS – Real vaqt narxi. Valyuta: USD
2.03
-0.05 (-2.40%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
2.03
-0.05 (-2.40%)
Yopilishda: May 12, 2026, 4:00 PM EDT
ALX Oncology Holdings Inc., klinik rivojlanish bosqichidagi immunoonkologiya kompaniyasi, Qo'shma Shtatlardagi saraton kasalligi bilan og'rigan bemorlar uchun davolash usullarini ishlab chiqishga qaratilgan. Kompaniyaning asosiy mahsuloti Evorpacept bo'lib, CD47 blokirovka qiluvchi terapevtik biologik vosita bo'lib, u boshqa saratonga qarshi vositalar bilan, jumladan, oshqozon/GEJ saratonini davolash uchun 2-bosqich klinik tadqiqotlarda bo'lgan ASPEN-06 bilan kombinatsiyalangan terapiya sifatida ishlab chiqilmoqda. Kompaniya Evorpacept kombinatsiyalangan dasturlari bo'yicha hamkorlik shartnomalariga ega, jumladan, Jazz Pharmaceuticals plc bilan zanidatamab uchun, u ko'krak bezi saratoni va boshqa qattiq o'smalarni davolash uchun 1b/2 bosqichli klinik sinovda; HER2 bilan ADC, fam-trastuzumab deruxtecan-nxki, ko'krak bezi saratoni bilan og'rigan bemorlarni davolash uchun 1-bosqichli klinik sinovda; ALX2004, qattiq o'smalarni davolash uchun 1-bosqichli klinik sinovda; MD Anderson Cancer Center bilan rituksimab va lenalidomid bilan indolent va agressiv NHL bilan og'rigan bemorlarni davolash uchun; va Sanofi bilan isatuximab va deksametazon bilan, qaytalangan yoki refrakter ko'p miyelom bilan og'rigan bemorlarni davolash uchun 1/2 bosqichli klinik sinovda. Kompaniya Leland Stanford Junior universiteti vasiylik kengashi bilan litsenziyalash shartnomalariga ega. Kompaniya 2015-yilda tashkil etilgan va Janubiy San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Athanasios Tsiatis M.D. | Senior Vice President of Clinical Development |
| Dr. Barbara J. Klencke M.D. | Chief Medical Officer |
| Dr. Lin Yeong-Liang M.D., M.S. | Senior Vice President of Drug Safety & Pharmacovigilance |
| Mr. Harish Shantharam C.F.A. | Chief Financial Officer |
| Mr. Jason W. Lettmann | CEO & Director |
| Mr. Jeff E. Knight M.P.H. | Chief Development & Operating Officer |
| Ms. Lisa Sauer | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Ms. Shelly Wong CPA | Senior VP of Finance & Chief Accounting Officer |
| Ms. Sue Naim | Senior Vice President of Clinical Operations |
| Ms. Venita De Almeida Ph.D. | VP & Head of Research Program Development |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-08 | 8-K | alxo-20260508.htm |
| 2026-04-20 | ARS | alxo_2025_ars.pdf |
| 2026-04-13 | 8-K | alxo-20260413.htm |
| 2026-03-09 | 10-K | alxo-20251231.htm |
| 2026-02-27 | 8-K | alxo-20260227.htm |
| 2026-01-21 | S-8 | alxo-20260121.htm |
| 2025-11-07 | 8-K | alxo-20251107.htm |
| 2025-09-12 | 8-K | alxo-20250911.htm |
| 2025-08-12 | 8-K | alxo-20250812.htm |
| 2025-06-12 | 8-K | alxo-20250611.htm |